Skip to main content
SpringerLink
Log in

Advances in the Management of Viral Infections

  • Chapter
  • First Online:
Book cover Infectious Complications in Cancer Patients

Part of the book series: Cancer Treatment and Research ((CTAR,volume 161))

  • 2174 Accesses

Abstract

Viral infections are common in cancer patients. The risk and severity of infection are influenced by patient, disease, treatment, and viral factors. Severe viral infections are more likely to occur in treatment regimens that are more immunosuppressive. Historically, the most frequent severe infections have been due to herpesviruses, but more recently, other pathogens, especially community respiratory and hepatitis viruses, have received increasing attention as major viral pathogens in cancer patients. Because of the new diagnostic assays and the introduction of better therapeutic options, knowledge of viral infections is important in optimizing antineoplastic therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Saral R (1988) Management of mucocutaneous herpes simplex virus infections in immunocompromised patients. Am J Med 85(2A):57–60

    PubMed  CAS  Google Scholar 

  2. Saral R, Burns WH, Prentice HG (1984) Herpes virus infections: clinical manifestations and therapeutic strategies in immunocompromised patients. Clin Haematol 13(3):645–660

    PubMed  CAS  Google Scholar 

  3. Khan SA, Wingard JR (2001) Infection and mucosal injury in cancer treatment. JNCI Monogr 29:31–36

    Article  Google Scholar 

  4. Herget GW, Riede UN, Schmitt-Graff A et al (2005) Generalized herpes simplex virus infection in an immunocompromised patient: report of a case and review of the literature. Pathol Res Pract 201:123–129

    Article  PubMed  Google Scholar 

  5. Pruneda RC, Almanza I (1987) Centrifugation-shell vial technique for rapid detection of herpes simplex virus cytopathic effect in vitro cells. J Clin Microbiol 25:423

    PubMed Central  PubMed  CAS  Google Scholar 

  6. Schmidt NJ, Dennis J, Devlin V et al (1983) Comparison of direct immunofluorescence and direct immunoperoxidase procedures for detection of herpes simplex virus antigen in lesion specimens. J Clin Microbiol 18:445–448

    PubMed Central  PubMed  CAS  Google Scholar 

  7. Gonik B, Seibel M, Berkowitz A et al (1991) Comparison of two enzyme-linked immunosorbent assays for detection of herpes simplex virus antigen. J Clin Microbiol 29:436–438

    PubMed Central  PubMed  CAS  Google Scholar 

  8. Nahass GT, Goldstein BA, Zhu WY et al (1992) Comparison of Tzanck smear, viral culture, and DNA diagnosis methods in detection of herpes simplex and varicella-zoster infection. JAMA 268:2541–2544

    Article  PubMed  CAS  Google Scholar 

  9. Meyers JD, Wade JC, Mitchell CD et al (1982) Multicenter collaborative trial of intravenous acyclovir for the treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 73A:229

    Article  Google Scholar 

  10. Mitchell CD, Gentry SR, Boen JR et al (1981) Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet 2:1389

    Article  Google Scholar 

  11. Shepp DH, Newton BA, Dandliker PS et al (1985) Oral acyclovir therapy for mucocutaneous herpes simplex virus infection in immunocompromised marrow transplant recipients. Ann Intern Med 102:783

    Article  PubMed  CAS  Google Scholar 

  12. Wade JC, Newton B, McLaren C et al (1982) Treatment of mucocutaneous herpes simplex virus infection after marrow transplantation with intravenous acyclovir: a double blind trial. Ann Intern Med 96:265

    Article  PubMed  CAS  Google Scholar 

  13. Selby PJ, Jameson B, Watson JG et al (1980) Parenteral acyclovir therapy for herpes virus infections in man. Lancet 2:1267

    Google Scholar 

  14. Soul-Lawton J, Seaber E, On N et al (1995) Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 39(12):2759–2764

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  15. Perry CM, Faulds D (1996) Valaciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52(5):754–772

    Article  PubMed  CAS  Google Scholar 

  16. Weller S, Blum MR, Doucette M et al (1993) Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 54(6):595–605

    Article  PubMed  CAS  Google Scholar 

  17. Saral R, Burns WH, Laskin OL et al (1981) Acyclovir prophylaxis of herpes-simplex-virus infections: a randomized, double-blind, controlled trial in bone marrow transplant recipients. N Engl J Med 305:63

    Article  PubMed  CAS  Google Scholar 

  18. Saral R, Ambinder RF, Burns WH et al (1983) Acyclovir prophylaxis against recrudescent herpes simplex virus infections in leukemia patients: a randomized, double-blind placebo controlled study. Ann Intern Med 99:773

    Article  PubMed  CAS  Google Scholar 

  19. Anderson H, Scarfee JH, Sutton RNP et al (1984) Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind placebo controlled trial. Br J Cancer 50:45–49

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  20. Wade JC, Newton B, Flournoy N, Meyers JD (1984) Oral acyclovir prophylaxis of herpes simplex virus infection after marrow transplant. Ann Intern Med 100:823

    Google Scholar 

  21. Wade JC, Newton B, Flournoy N et al (1984) Acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 99:773–776

    Google Scholar 

  22. Saral R (1990) Management of acute viral infections. NCI Monogr 9:107–110

    PubMed  Google Scholar 

  23. Wingard JR (1993) Viral infections in leukemia and bone marrow transplant patients. Leuk Lymphom 11:115–125

    Article  Google Scholar 

  24. Ambinder RF, Burns WH, Lietman PS et al (1984) Prophylaxis: a strategy to minimize antiviral resistance. Lancet 1:1154–1155

    Article  PubMed  CAS  Google Scholar 

  25. Saral R, Ambinder RF, Burns WH et al (1983) Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 99(6):773–776

    Article  PubMed  CAS  Google Scholar 

  26. Wade JC, McLaren C, Meyers JD (1983) Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis 148:1077–1082

    Article  PubMed  CAS  Google Scholar 

  27. Burns WH, Santos GW, Saral R et al (1982) Isolation and characterizations of resistant herpes simplex virus after acyclovir therapy. Lancet 2:421

    Article  Google Scholar 

  28. McLaren C, Chen MS, Ghazzouli I et al (1985) Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir. Antimicrob Agent Chemother 28:740–744

    Article  CAS  Google Scholar 

  29. Safrin S, Assakeen T, Follansbee S, Mills J (1990) Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 161:1078

    Article  PubMed  CAS  Google Scholar 

  30. Safrin S, Crumpacker C, Chatis, et al (1991) A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 325:551–555

    Google Scholar 

  31. Randolph-Habecker J, Iwata M, Torok-Storb B (2002) Cytomegalovirus mediated myelosuppression. J Clin Virol 25(Suppl 2):S51–S56

    Article  PubMed  CAS  Google Scholar 

  32. Torok-Storb B, Boeckh M, Hoy C et al (1997) Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. Blood 90:2097–2102

    PubMed  CAS  Google Scholar 

  33. Choi JH, Kim DW, Cho SG et al (1997) Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation. Bone Marrow Transplant 19:187–190

    Article  PubMed  CAS  Google Scholar 

  34. Leland DS, Hansing RL, French ML (1989) Clinical experiences with cytomegalovirus isolation using conventional cell cultures and early antigen detection in centrifugation-enhanced shell vial cultures. J Clin Microbiol 27:1159–1162

    PubMed Central  PubMed  CAS  Google Scholar 

  35. Gleaves CA, Smith TF, Shuster EA, Pearson GR (1985) Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol 21:217

    PubMed Central  PubMed  CAS  Google Scholar 

  36. Boeckh M, Bowden RA, Goodrich JM et al (1992) Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 80:1358–1364

    PubMed  CAS  Google Scholar 

  37. van der Bij W, Torensma R, van Son WJ et al (1988) Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 25:179–188

    Article  PubMed  Google Scholar 

  38. Jiwa NM, van de Rijke FM, Mulder A et al (1989) An improved immunocytochemical method for detection of human cytomegalovirus antigens in peripheral blood leucocytes. Histochemistry 91:345–349

    Article  PubMed  CAS  Google Scholar 

  39. Spector SA, Merrill R, Wolf D et al (1992) Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 30:2359–2365

    PubMed Central  PubMed  CAS  Google Scholar 

  40. Brytting M, Xu W, Wahren B et al (1992) Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol 30:1937–1941

    PubMed Central  PubMed  CAS  Google Scholar 

  41. Einsele H, Steidle M, Vallbracht A et al (1991) Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 77:1104–1110

    PubMed  CAS  Google Scholar 

  42. Nolte FS, Emmens RK, Thurmond C et al (1995) Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification. J Clin Microbiol 33:1263–1266

    PubMed Central  PubMed  CAS  Google Scholar 

  43. Landry ML, Fergussen D (1993) Comparison of quantitative cytomegalovirus antigenemia assay with culture methods and correlation with clinical disease. J Clin Microbiol 31:2851–2856

    PubMed Central  PubMed  CAS  Google Scholar 

  44. Schmidt CA, Oettle H, Wilborn F et al (1994) Demonstration of cytomegalovirus after bone marrow transplantation by polymerase chain reaction, virus culture and antigen detection in buffy coat leukocytes. Bone Marrow Transplant 83:71–75

    Google Scholar 

  45. Shepp DH, Dandliker PS, deMiranda P, et al (1985) Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl] guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 103:368

    Google Scholar 

  46. Emanuel D, Cunningham I, Jules-Elysee K et al (1988) Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 109:777–782

    Article  PubMed  CAS  Google Scholar 

  47. Reed EC, Bowden RA, Dandliker PS et al (1988) Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 109:783–788

    Article  PubMed  CAS  Google Scholar 

  48. Schmidt GM, Kovacs A, Zaia JA et al (1988) Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 46:905–907

    Article  PubMed  CAS  Google Scholar 

  49. Reed EC, Wolford JL, Kopecky KJ et al (1990) Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med 112(7):505–510

    Article  PubMed  CAS  Google Scholar 

  50. Ljungman P, Cordonnier C, Einsele H et al (1998) Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 21:473–476

    Article  PubMed  CAS  Google Scholar 

  51. Goodrich JM, Bowden RA, Fisher L et al (1993) Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173–178

    Article  PubMed  CAS  Google Scholar 

  52. Winston DJ, Ho WG, Bartoni K et al (1993) Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 118:179–184

    Article  PubMed  CAS  Google Scholar 

  53. Schmidt GM, Horak DA, Niland JC et al (1991) A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplant patients. N Engl J Med 324:1005–1011

    Article  PubMed  CAS  Google Scholar 

  54. Goodrich JM, Mori M, Gleaves CA et al (1991) Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplant. N Engl J Med 325:1601–1607

    Article  PubMed  CAS  Google Scholar 

  55. Drew WL, Ives D, Lalezari JP et al (1995) (for the Syntex Cooperative Oral Ganciclovir Study Group). Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 333:615–620

    Article  PubMed  CAS  Google Scholar 

  56. Drew WL, Miner RC, Busch DF et al (1991) Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 163:716–719

    Article  PubMed  CAS  Google Scholar 

  57. Ayala E, Greene J, Sandin R et al (2006) Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37(9):851–856

    Article  PubMed  CAS  Google Scholar 

  58. Einsele H, Reusser P, Bornhäuser M et al (2006) Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107(7):3002–3008

    Article  PubMed  CAS  Google Scholar 

  59. van der Heiden PL, Kalpoe JS, Barge RM et al (2006) Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 37(7):693–698

    Google Scholar 

  60. Busca A, de Fabritiis P, Ghisetti V et al (2007) Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis 9(2):102–107

    Article  PubMed  CAS  Google Scholar 

  61. Volin L, Barkholt L, Nihtinen A et al (2008) An open-label randomised study of oral valganciclovir versus intravenous ganciclovir for pre-emptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation [abstract]. In: 34th annual meeting of the European Group for Blood and Marrow Transplantation. Florence, Italy

    Google Scholar 

  62. Moretti S, Zikos P, Van Lint MT et al (1998) Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant 22(2):175–180

    Google Scholar 

  63. Goodrich JM, Boeckh M, Bowden R (1994) Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 19:287–298

    Article  PubMed  CAS  Google Scholar 

  64. Forman SJ, Zaia JA (1994) Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood 83:2392–2398

    PubMed  CAS  Google Scholar 

  65. Devine SM, Wingard JR (1994) Viral infections in severely immunocompromised cancer patients. Support Care Cancer 2:355–368

    Article  PubMed  CAS  Google Scholar 

  66. Boeckh M, Nichols G, Papanicolaou G et al (2003) Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9(9):543–558

    Article  PubMed  Google Scholar 

  67. Ljungman P, Deliliers GL, Platzbecker U et al (2001) Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The infectious diseases working party of the European Group for Blood and Marrow Transplantation. Blood 97:388–392

    Article  PubMed  CAS  Google Scholar 

  68. Chou S, Guentzel S, Michels R et al (1995) Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 172:239–242

    Article  PubMed  CAS  Google Scholar 

  69. Emery VC, Griffiths PD (2000) Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl AcadSc i USA 97:8039–8044

    Article  CAS  Google Scholar 

  70. Razis E, Cook P, Mittelman A, Ahmed T (1994) Treatment of ganciclovir resistant cytomegalovirus with foscarnet: a report of two cases occurring after bone marrow transplantation. Leuk Lymphom 12:477–480

    Article  CAS  Google Scholar 

  71. Meyers JD, Reed EC, Shepp DH et al (1988) Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 318:70–75

    Article  PubMed  CAS  Google Scholar 

  72. Prentice HG, Gluckman E, Powles RL et al (1994) Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 343:749–753

    Article  PubMed  CAS  Google Scholar 

  73. Ljungman P, de La Camara R, Milpied N et al (2002) Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 99(8):3050–3056

    Article  PubMed  CAS  Google Scholar 

  74. Bowden RA, Slichter SJ, Sayers MH et al (1991) Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 78:246–250

    PubMed  CAS  Google Scholar 

  75. Bowden RA, Sayers M, Flournoy N et al (1986) Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314:1006–1010

    Article  PubMed  CAS  Google Scholar 

  76. Mackinnon S, Burnett AK, Crawford RJ et al (1988) Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation. J Clin Pathol 41:948–950

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  77. Miller W, McCullough J, Balfour HH et al (1988) Prevention of CMV infection by blood products: a randomized trial (abstract K128). J Cell Biochem 12(Suppl. C):93

    Google Scholar 

  78. De Witte T, Schattenbereg A, Van Dijk BA et al (1990) Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 50:964–968

    Article  PubMed  Google Scholar 

  79. Bowden RA, Slichter SJ, Sayers M et al (1995) A comparison of filtered leukocyte-reduced cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 85:3598–3603

    Google Scholar 

  80. Winston DJ, Ho WG, Lin CH et al (1987) Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 106:12–18

    Article  PubMed  CAS  Google Scholar 

  81. Bass EB, Powe NR, Goodman SN et al (1993) Efficacy of intravenous immune globulin in preventing complications of bone marrow transplantation: a meta analysis. Bone Marrow Transplant 12:273–282

    PubMed  CAS  Google Scholar 

  82. Messori A, Rampazzo R, Scroccaro G, Martini N (1994) Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 13:163–167

    PubMed  CAS  Google Scholar 

  83. Bowden RA, Fisher LD. Rogers K et al (1991) Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 164:483–487

    Google Scholar 

  84. Guglielmo BJ, Wong-Beringer A, Linkcr CA (1994) Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant 13:499–510

    PubMed  CAS  Google Scholar 

  85. Sullivan KM, Kopecky KJ, Jocum J et al (1990) Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705–712

    Article  PubMed  CAS  Google Scholar 

  86. Locksley RM, Flournoy N, Sullivan KM, Meyers JD (1985) Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 152:1172–1181

    Article  PubMed  CAS  Google Scholar 

  87. Atkinson K, Meyers JD, Storb R et al (1980) Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation 29:47–50

    Article  PubMed  CAS  Google Scholar 

  88. Schiller GJ, Nimer SD. Gajewski JL, Golde D (1991) Abdominal presentation of varicella-zoster infection in recipients of allogeneic bone marrow transplantation. Bone Marrow Transplant 7:489–491

    Google Scholar 

  89. Balfour HH Jr, Bean B, Laskin OL et al and the Burroughs Wellcome Collaborative Acyclovir Study Group (1983) Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 308:1448–1453

    Google Scholar 

  90. Meyers JD, Wade JC, Shepp DH, Newton B (1984) Acyclovir treatment of varicella-zoster virus infection in the compromised host. Transplantation 37:571

    Article  PubMed  CAS  Google Scholar 

  91. Shepp DH, Dandliker PS, Meyers JD (1986) Treatment of varicella-zoster virus infection in severely immunocompromised patients: a randomized comparison of acyclovir and vidarabine. N Engl J Med 314:208–212

    Article  PubMed  CAS  Google Scholar 

  92. McKendrick MW, McGill JI, White JE, Wood MJ (1986) Oral acyclovir in acute herpes zoster. Br Med J 293:1529–1532

    Google Scholar 

  93. Ljungman P, Lönnqvist B, Ringdén O et al for the Nordic Bone Marrow Transplant Group (1989) A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Bone Marrow Transplant 4:613–615

    Google Scholar 

  94. Boivin G, Edleman CK, Pedneault L et al (1994) Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 170:68–75

    Article  PubMed  CAS  Google Scholar 

  95. Safrin S, Berger TG, Gilson I et al (1991) Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med 115:19–21

    Article  PubMed  CAS  Google Scholar 

  96. Zaia JA, Levin MJ, Preblud SR et al (1983) Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 147:737

    Article  PubMed  CAS  Google Scholar 

  97. Gershon AA (1985) Live attenuated varicella vaccine: perspective. J Infect Dis 152:859

    Article  PubMed  CAS  Google Scholar 

  98. Gershon AA, Steinberg SP, and the Varicella Vaccine Collaborative Study Group of the NIAID (1989) Persistence of immunity of varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 320:892

    Google Scholar 

  99. Gershon AA, Steinberg SP, and the National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group (1990) Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. J Infect Dis 161:661

    Google Scholar 

  100. Lawrence R, Gershon AA, Holzman R et al (1988) The risk of zoster after varicella vaccination in children with leukemia. N Engl J Med 318:543

    Article  PubMed  CAS  Google Scholar 

  101. Ljungman P, Wang FZ, Nilsson C et al (2003) Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study. Support Care Cancer 11:739–741

    Google Scholar 

  102. Hata A, Asanuma H, Rinki M et al (2002) Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347:26–34

    Article  PubMed  Google Scholar 

  103. Ballerini P, Gaidano G, Inghirami G et al (1991) Multiple genetic alterations in AIDS-associated lymphomas. Blood 78:327

    Google Scholar 

  104. Knowles DM, Cesarman E, Chadburn A et al (1995) Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552–565

    PubMed  CAS  Google Scholar 

  105. Bakker NA, van Imhoff GW, Verschuuren EAM, van Son WJ (2007) Presentation and early detection of post-transplantation lymphoproliferative disorder after solid organ transplantation. Transpl Inter 20:207–218

    Article  CAS  Google Scholar 

  106. Styczynski J, Einsele H, Gil L, Ljungman P (2009) Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 11:383–392

    Article  PubMed  CAS  Google Scholar 

  107. Shapiro RS, McClain K, Frizzera G et al (1988) Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71(5):1234–1243

    PubMed  CAS  Google Scholar 

  108. Curtis RE, Travis LB, Rowlings PA et al (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94(7):2208–2216

    PubMed  CAS  Google Scholar 

  109. Meerbach A, Wutzler P, Häfer R et al (2008) Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol 80(3):441–454

    Article  PubMed  CAS  Google Scholar 

  110. Carrigan DR, Drobyski WR, Russler SK et al (1991) Interstitial pneumonitis associated with human herpesvirus six (HHV-6) infection in marrow transplant patients. Lancet 338:147

    Article  PubMed  CAS  Google Scholar 

  111. Cone RW, Hackman RC, Huang MW et al (1993) Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med 329:156

    Article  PubMed  CAS  Google Scholar 

  112. Drobyski WR, Knox KK, Majewski D, Carrigan DR (1994) Fatal encephalitis due to variant B human herpesvirus 6 infection in a bone marrow transplant recipient. N Engl J Med 330:1356

    Article  PubMed  CAS  Google Scholar 

  113. Drobyski WR, Dunne WM, Burd EM (1993) Human herpesvirus 6 (HHV-6) infection in allogeneic bone marrow transplant recipients: I. Evidence for a marrow suppressive role for HHV-6 in vivo. J Infect Dis 167:735

    Article  PubMed  CAS  Google Scholar 

  114. Carrigan DR, Knox KK (1994) Human herpesvirus 6 (HHV-6) isolation from bone marrow: HHV-6-associated bone marrow suppression in bone marrow transplant patients. Blood 84:3307–3310

    PubMed  CAS  Google Scholar 

  115. Burns WH, Sandford GR (1990) Susceptibility of human herpesvirus 6 to antivirals in vitro. J Infect Dis 162:634–637

    Article  PubMed  CAS  Google Scholar 

  116. Zerr DM, Gupta D, Huang ML et al (2002) Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin Infect Dis 34(3):309–317

    Article  PubMed  CAS  Google Scholar 

  117. Quinnan GV Jr, Kirmani N, Rook AH et al (1982) Cytotoxic cells in cytomegalovirus infections. HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med 307:7

    Article  PubMed  Google Scholar 

  118. Reusser P, Riddel SR, Meyers SD, Greenberg PD (1991) Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373–1380

    PubMed  CAS  Google Scholar 

  119. Quinnan GV Jr, Burns WH, Kirmani N et al (1984) HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in infections. Rev Infect Dis 6:156–163

    Article  PubMed  Google Scholar 

  120. Riddel SR, Walter BA, Gilbert MJ, Greenberg PD (1994) Selective reconstitution of CD8 cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant 14:S78–S84

    Google Scholar 

  121. Riddell SR, Watanabe KS, Goodrich JM et al (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 257:238

    Article  PubMed  CAS  Google Scholar 

  122. Riddell SR, Reusser P, Greenberg PD (1991) Cytotoxic T-cells specific for cytomegalovirus: a potential therapy for immunocompromised hosts. Rev Infect Dis 13:966

    Article  Google Scholar 

  123. Walter EA, Greenberg PD, Gilbert MJ et al (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow transplant by transfer of T-cell clones from the donor. N Engl J Med 333:1038–1044

    Article  PubMed  CAS  Google Scholar 

  124. Papadopoulos EB, Ladanyi M, Emanuel D et al (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185–1191

    Article  PubMed  CAS  Google Scholar 

  125. Rooney CM, Smith CA, Ng CY, Loftin SK et al (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92(5):1549–1555

    Google Scholar 

  126. Heslop HE, Perez M, Benaim E et al (1999) Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant. J Clin Apher 14(3):154–156

    Google Scholar 

  127. Lucas KG, Sun Q, Burton RL et al (2000) A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants. Hum Gene Ther 11(10):1453–1463

    Google Scholar 

  128. Firpi RJ, Nelson DR (2008) Management of viral hepatitis in hematologic malignancies. Blood Rev 22(3):117–126

    Article  PubMed  CAS  Google Scholar 

  129. Martyak LA, Taqavi E, Saab S (2008) Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 28(1):28–38

    Article  PubMed  CAS  Google Scholar 

  130. Lok AS, McMahon BJ (2007) Chronic hepatitis B. Hepatology 45(2):507–539

    Article  PubMed  CAS  Google Scholar 

  131. Liang R (2009) How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113:3147–3153

    Article  PubMed  CAS  Google Scholar 

  132. Lok AS, Lai CL, Leung N et al (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714–1722

    Article  PubMed  CAS  Google Scholar 

  133. Peffault de Latour R, Lévy V, Asselah T et al (2004) Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 103:1618–1624

    Google Scholar 

  134. Shuhart MC, Myerson D, Childs BH (1994) Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood 84:3229–3235

    PubMed  CAS  Google Scholar 

  135. Ilan Y, Nagler A, Adler R et al (1993) Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 104:1818–1821

    PubMed  CAS  Google Scholar 

  136. Flomenberg P, Babbitt J, Drobyski WR et al (1994) Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 169:775–781

    Article  PubMed  CAS  Google Scholar 

  137. Chakrabarti S, Mautner V, Osman H et al (2002) Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100(5):1619–1627

    Article  PubMed  CAS  Google Scholar 

  138. Sivaprakasam P, Carr TF, Coussons M et al (2007) Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention. J Pediatr Hematol Oncol 29(2):81–85

    Article  PubMed  Google Scholar 

  139. Boeckh M (2008) The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Hematol 143:455–467

    Google Scholar 

  140. Bowden RA (1997) Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 102:27–30

    Article  PubMed  CAS  Google Scholar 

  141. Hall CB, Powell KR, MacDonald NE et al (1986) Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 315:77–81

    Article  PubMed  CAS  Google Scholar 

  142. Rabella N, Rodriguez P, Labeaga R et al (1999) Conventional respiratory viruses recovered from immunocompromised patients: clinical considerations. Clin Infect Dis 28:1043–1048

    Article  PubMed  CAS  Google Scholar 

  143. Engelhard D, Nagler A, Hardan I et al (1993) Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 11:1–5

    PubMed  CAS  Google Scholar 

  144. Smith DW, Frankel LR. Mathers LH et al (1991) A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 325:24–29

    Google Scholar 

  145. Whimbey E, Champlin RE, Englund JA et al (1995) Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 16:393–399

    Google Scholar 

  146. Chemaly RF, Ghosh S, Bodey GP et al (2006) Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 85(5):278–287

    Article  Google Scholar 

  147. Boeckh M, Englund J, Li Y, Miller C et al (2007) Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 44(2):245–249

    Article  PubMed  CAS  Google Scholar 

  148. de Fontbrune FS, Robin M, Porcher R et al (2007) Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 45(8):1019–1024

    Article  PubMed  CAS  Google Scholar 

  149. Englund JA, Boeckh M, Kuypers J et al (2006) Fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 144(5):344–349

    Article  PubMed  Google Scholar 

  150. Englund JA, Anderson LJ, Rhame FS (1991) Nosocomial transmission of respiratory syncytial virus in immunocompromised adults. J Clin Microbiol 29:115–119

    PubMed Central  PubMed  CAS  Google Scholar 

  151. Whimbey E, Elting LS, Cough RB et al (1994) Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 13:437–440

    PubMed  CAS  Google Scholar 

  152. Wingard JR (2008) Influenza: preparedness for an inevitable “Emergency” for the oncology and BMT unit. J Natl Compr Cancer Netw 6(2):215–222

    Google Scholar 

  153. Vu D, Peck AJ, Nichols WG et al (2007) Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 45(2):187–193

    Article  PubMed  CAS  Google Scholar 

  154. Arthur RR, Shah KV, Baust SJ et al (1986) Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med 315:230–234

    Article  PubMed  CAS  Google Scholar 

  155. Russell SJ, Vowels MR, Vale T (1994) Haemorrhagic cystitis in paediatric bone marrow transplant patients: an association with infective agents. GVHD and prior cyclophosphamide. Bone Marrow Transplant 13:533–539

    PubMed  CAS  Google Scholar 

  156. Azzi A, Fanci R, Bosi A et al (1994) Monitoring of polyomavirus BK viruria in bone marrow transplantation patients by DNA hybridization assay and by polymerase chain reaction: an approach to assess the relationship between BK viruria and hemorrhagic cystitis. Bone Marrow Transplant 14:235–240

    PubMed  CAS  Google Scholar 

  157. Schneider EM, Dörries K (1983) High frequency of polyomavirus infection in lymphoid cell preparations after allogeneic bone marrow transplantation. Transplant Proc 25:1271–1273

    Google Scholar 

  158. Drummond JE, Shah KV, Saral R et al (1987) BK virus specific humoral and cell mediated immunity in allogeneic bone marrow transplant (BMT) recipients. J Med Virol 23:331–344

    Article  PubMed  CAS  Google Scholar 

  159. Held TK, Biel SS, Nitsche A, Kurth A et al (2000) Treatment of BK virus-associated hemorrhagic cystitis and simultaneous CMV reactivation with cidofovir. Bone Marrow Transplant 26(3):347–350

    Article  PubMed  CAS  Google Scholar 

  160. Dropulic LK, Jones RJ (2008) Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplant 41(1):11–18

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Florida, 1600 SW Archer Road, PO Box 100277, Gainesville, FL, 32610, USA

    Jack W. Hsu

  2. Department of Medicine, University of Florida College of Medicine, 1600 SW Archer Road, PO Box 100278, Gainesville, FL, 32610–0278, USA

    John R. Wingard

Authors
  1. Jack W. Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John R. Wingard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John R. Wingard .

Editor information

Editors and Affiliations

  1. Div. Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

    Valentina Stosor

  2. Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

    Teresa R. Zembower

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Hsu, J.W., Wingard, J.R. (2014). Advances in the Management of Viral Infections. In: Stosor, V., Zembower, T. (eds) Infectious Complications in Cancer Patients. Cancer Treatment and Research, vol 161. Springer, Cham. https://doi.org/10.1007/978-3-319-04220-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-04220-6_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-04219-0

  • Online ISBN: 978-3-319-04220-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation